Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc.

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

AstraZeneca

GlaxoSmithKline

Novartis

AstraZenca, GlaxoSmithKline, Novartis and Eli Lilly are using artificial intelligence systems to help in drug development, decision-making, and more.

These 4 Drugmakers Are Using AI to Improve Their Products. Does It Make Them Better Buys?

Merck

Only one of these stocks has performed well this year, but both are worth buying and holding over the long term.

2 Forever Pharma Stocks to Buy Now

Eli Lilly and Co.'s (NYSE:LLY) anti-diabetic and obesity drug tirzepatide is the most valuable project in the pharmaceutical industry's pipeline, according to a report from EvaluatePharma.

Eli Lilly, Novartis Have Most Valuable Pipeline Drugs

AbbVie

Johnson & Johnson

Pfizer

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

SUZHOU, China, Aug. 12, 2020 /PRNewswire/ -- Innovent Biologics, Inc.

Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT® (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China

Gilead Sciences

iShares Nasdaq Biotechnology ETF

Moderna

Novo Nordisk

Regeneron Pharmaceuticals

Roche Holding AG

Sanofi

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

The biotech sector had a troubled Q2, as doctor visits were curtailed and new Rx'es were in short supply; R&D efforts were also harmed.

Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

Abbott Labs

No one wants COVID-19 vaccines to fail. But if you want to hedge for the possibility, check out these solid stocks.

3 Large-Cap Stocks That Should Soar If Coronavirus Vaccines Flop

Novavax

Two big drugmakers and one small biotech appear to be great picks right now.

3 Top Coronavirus Stocks to Buy in August

SUZHOU, China, Aug. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc.

Innovent and Lilly Release Clinical Trial Results of Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum Chemotherapy as First-Line Treatment for Nonsquamous NSCLC in an Oral Presentation at IASLC WCLC 2020 Virtual Presidential Symposium

Eli Lilly and Co.’s (LLY) new migraine medication, Reyvow, is giving the pharma giant a bit of a headache.

Early Sales of Eli Lilly's Migraine Drug Disappoint

Shares of Eli Lilly & Co. LLY, +1.31% gained 0.6% in premarket trading on Wednesday, the day after the National Institutes of Health said it plans to study whether several experimental monoclonal antibodies can treat hospitalized COVID-19 patients.

NIH to test Lilly's experimental monoclonal antibody treatment in mild and moderate COVID-19 cases

The National Institutes of Health is starting a head-to-head trial of several antibody treatment candidates.

Eli Lilly's COVID-19 Treatment Candidate Will Be the First Tested in NIH's Phase 3 Study

The trials, called ACTIV-2 and ACTIV-3, will look at U.S. drugmaker Eli Lilly's experimental treatment known as LY-CoV555, which is being developed in partnership with Canadian biotech AbCellera.

U.S. government begins two trials testing Eli Lilly's coronavirus antibody drug

The drugmaker has put its COVID-19 antibody clinical trial on wheels so it can involve patients at nursing homes, which have been particularly hard hit by the pandemic.

Eli Lilly Brings a Coronavirus Drug Study Directly to Senior Care Facilities -- in RVs

Should you go with the nimble biotech or the big pharmaceutical company?

Better Coronavirus Stock: Regeneron or Eli Lilly?

"We wanted to see if we could help people in nursing homes because the disease has been so devastating," Dr. Dan Skovronsky of Eli Lilly told CNBC.

Eli Lilly is using mobile labs to study if its antibody drug can prevent Covid-19 in nursing homes

Eli Lilly stock jumped early Monday after the drugmaker announced the start of Phase 3 testing to determine if one of its drugs can help prevent Covid-19 in nursing home residents and staff.
The post Eli Lilly Stock Jumps As Coronavirus Drug Enters Phase 3 Testing appeared first on Investor's Business Daily.

Eli Lilly Stock Jumps As Coronavirus Drug Enters Phase 3 Testing

Shares of Eli Lilly & Co. LLY, -1.77% gained 1.1% in premarket trading on Monday after the drugmaker said it started a Phase 3 trial for a treatment that aims to prevent COVID-19 infections in residents and workers in nursing homes.

Lilly's stock rises as it announces late-stage trial for COVID-19 drug in nursing homes

U.S. drugmaker Eli Lilly said on Monday it is beginning a late-stage trial to study whether one of its experimental Covid-19 antibody treatments can prevent the virus' spread in residents and staff in U.S. nursing homes.

Eli Lilly starts late-stage study of coronavirus drug in nursing homes

INDIANAPOLIS, Aug. 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the initiation of BLAZE-2, a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 in residents and staff at long-term care facilities in the U.S.

Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)

These two big drugmakers have tremendous prospects for their respective COVID-19 programs. Here's which one could be the bigger winner.

Better Coronavirus Stock: AstraZeneca vs. Eli Lilly

Eli Lilly and Company (LLY) CEO Dave Ricks on Q2 2020 Results - Earnings Call Transcript

Eli Lilly and Co said on Thursday it had started mid-stage testing of one of its experimental treatments for COVID-19, as the drugmaker reported second-quarter sales that missed estimates due to the pandemic.

Eli Lilly starts mid-stage study of COVID-19 treatment

Eli Lilly (LLY) reports mixed Q2 results. Total revenues in the quarter hurt by the coronavirus pandemic

News for Eli Lilly Stock (LLY)